Showing results (231-240 of 281) with videos related to
Sort By:
Pageof 29
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 2, 2018
EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor OsimertinibQi Zhang, Xu-Chao Zhang, Jin-Ji Yang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2014
Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylationJin-Ji Yang, Xu-Chao Zhang, Jian Su, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 23, 2017
Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade ImmunotherapySi-Pei Wu, Ri-Qiang Liao, Hai-Yan Tu, et al.Optics Letters|June 2, 2018
High-energy single-frequency 167 nm deep-ultraviolet laserJia-Jia Li, Feng-Feng Zhang, Zhi-Min Wang, et al.Journal of Thoracic Disease|October 23, 2023
Expression of <i>EGFR</i>-mutant proteins and genomic evolution in <i>EGFR</i>-mutant transformed small cell lung cancerShi-Ling Zhang, Chan-Yuan Zhang, Yu-Qing Chen, et al.Oncotarget|August 18, 2016
Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterationsNa-Na Lou, Xu-Chao Zhang, Hua-Jun Chen, et al.Lung Cancer (Amsterdam, Netherlands)|August 27, 2024
Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimenKe-Jun Liu, Hong-Rui Li, Quan-Quan Tan, et al.Science Progress|March 19, 2025
The combination of immune checkpoint inhibitor and chemotherapy may be efficacious for advanced non-small cell lung cancer with near-loop insertions of <i>EGFR</i> exon 20: A retrospective analysisKe-Jun Liu, Hong-Rui Li, Quan-Quan Tan, et al.Thoracic Cancer|July 7, 2018
Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancerJin Kang, Hua-Jun Chen, Xu-Chao Zhang, et al.Cell Reports|July 12, 2023
T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activityYuanbin Cui, Tingjie Yuan, Ying Wang, et al.Pageof 29